New hope for aggressive uterine cancer: vaccine and drug combo trial launches
NCT ID NCT06253494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized vaccine plus three other drugs in 60 adults with advanced HER2-positive endometrial cancer that returned after treatment. The vaccine is made from each patient's own blood cells and targets the HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF ENDOMETRIUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?